04Jul 2015
endocrine society

. J Clin Endocrinol Metab. 2015 Jul;100(7):2784-2792. Epub 2015 May 8

Denosumab allows for supra-physiologic doses of calcitriol resulting in decreased parathyroid secretion and parathyroid hyperplasia. Supervised administration and weekly laboratory and clinical monitoring of serum calcium are recommended during the first month to prevent hypocalcemia

Autor: Chen CL, Chen NC, Liang HL, Hsu CY, Chou KJ, Fang HC, Lee PT
04Jul 2015
Springer

J Bone Miner Res. 2015 Jul;30(7):1119-33. doi: 10.1002/jbmr.2536. Epub 2015 May 7.

We propose a desirable range of 20 to 40 ng/mL (50 to 100 nmol/L), provided precise and accurate assays are used. Although slightly lower levels, 15 to 20 ng/mL, may be sufficient for some infants and adults, higher levels, 40 to 60 ng/mL, may still be safe. This desirable range allows physicians to tailor treatment while taking season, lifestyle, vitamin D intake, and other sources of variation into account. We reserve 25OHD measurements for at-risk patients, defined by disease or lifestyle, and the use of 25OHD assays calibrated against the recommended international standards. Most target groups reach desirable target levels by a daily intake of 400 to 600 IU for children and 800 IU for adults. A total daily allowance of vitamin D of up to 1000 IU in the pediatric age groups, and up to 2000 IU in adults, tailored to an individual patient risk profile, is probably safe over long durations. Additional data are needed to validate the proposed range and vitamin D doses, especially in children, pregnant women, and non-white populations. © 2015 American Society for Bone and Mineral Research.

Autor: El-Hajj Fuleihan G, Bouillon R, Clarke B, Chakhtoura M, Cooper C, McClung M, Singh RJ.
04May 2015
wiley-logo

J Bone Miner Res. 2015 May;30(5):934-44. doi: 10.1002/jbmr.2442.

The results suggest almost all patients who have received six annual ZOL infusions can stop medication for up to 3 years with apparent maintenance of benefits.

Autor: Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R
04May 2015
wiley-logo

J Bone Miner Res. 2015 May;30(5):929-33. doi: 10.1002/jbmr.2410.

We conclude that the effects of bisphosphonates on fracture prevention in osteogenesis imperfecta are inconclusive. Adequately powered trials with a fracture endpoint are needed to further investigate the risks and benefits of bisphosphonates in this condition.

Autor: Hald JD, Evangelou E, Langdahl BL, Ralston SH.
04May 2015
bone logo

Bone. 2015 May 16. pii: S8756-3282(15)00195-7. doi: 10.1016/j.bone.2015.05.016.

Although TBS changes with osteoporosis treatment, the magnitude is less than that of aBMD of the spine, and it is not clear how change in TBS relates to fracture risk reduction. TBS may also have a role in the assessment of fracture risk in some causes of secondary osteoporosis (e.g., diabetes, hyperparathyroidism and glucocorticoid-induced osteoporosis). In conclusion, there is a role for TBS in fracture risk assessment in combination with both aBMD and FRAX.

Autor: Harvey NC, Glüer CC, Binkley N, McCloskey EV, Brandi ML, Cooper C, Kendler D, Lamy O, Laslop A, Camargos BM, Reginster JY, Rizzoli R, Kanis JA.
04May 2015
wiley-logo

Journal of Bone and Mineral Research 2015; Volume 30, Issue 6, pages 970–975

The data show that hyponatremia is associated with up to a doubling in the risk of hip and morphometric spine fractures, independent of BMD. Further studies, to determine how hyponatremia causes fractures and if correction of hyponatremia decreases fractures, are needed.

Autor: Sophie A Jamal*, Spyridon Arampatzis, Stephanie Litwack Harrison, Roxana C Bucur, Kristine Ensrud, Eric S Orwoll and Douglas C Bauer.
04May 2015
wiley-logo

Journal of Bone and Mineral Research 2015; Volume 30, Issue 6, pages 951–966

The goal of this review is to clarify the biomechanical mechanisms and to make recommendations for systematically evaluating phenotypic changes in mouse bones, with a focus on long-bone diaphyses and cortical bone. Further, minimum reportable standards for testing conditions and outcome variables are suggested that will improve the comparison of data across studies. Basic biomechanical principles are reviewed, followed by a description of the cross-sectional morphological properties that best inform the net cellular effects of a given experimental perturbation and are most relevant to biomechanical function.

Autor: Karl J Jepsen, Matthew J Silva, Deepak Vashishth, X Edward Guo and Marjolein CH van der Meulen.
04May 2015
wiley-logo

J Bone Miner Res. 2015 May;30(5):753-64. doi: 10.1002/jbmr.2496.

Combined therapy remains a potentially valuable approach to therapy. Because studies of antifracture efficacy comparing combined with single therapy are unlikely to be performed in humans, efforts should be directed toward improving methods of quantifying the net effects of combined therapy on bone’s material composition, microarchitecture, and strength.

Autor: E, Martin TJ.
04May 2015
Springer

Osteoporos Int 19 May online 2015. DOI 10.1007/s00198-015-3160-8

Postmenopausal women aged 50 years and older with a recent DRF had lower bone and muscle strength in both the upper and lower extremities com- pared to the women without a recent DRF, despite no differences in DXA-derived aBMD at the femoral neck or spine and no difference in bone strength at the tibia shaft. Although DXA is clinically used for diagnosing osteoporosis in individual patients, this study provides further support for the notion that aBMD alone may not provide a sufficient predictor for DRF risk.

Autor: K. Crockett, C. M. Arnold, J. P. Farthing, P. D. Chilibeck, J. D. Johnston, B. Bath,A. D. G. Baxter-Jones,S. A. Kontulainen.
04May 2015
Springer

Osteoporos Int 19 may 2015 on line. DOI 10.1007/s00198-015-3168-0

PPI use was associated with fracture in young adults, but overall evidence did not support a PPI-fracture relationship in children. Young adults who use PPIs should be cautioned regarding potentially increased risk for fracture, even if they lack traditional fracture risk factors.

Autor: D. E. Freedberg, K. Haynes, M. R. Denburg, B. S. Zemel, M. B. Leonard, J. A. Abrams, Y.-X. Yang.